Modified chitin binding domain and uses thereof
Compositions and methods are provided for reversibly binding chitin-binding domain (CBD) to a chitin or equivalent substrate under non-denaturing conditions. CBD from either prokaryotes or eukaryotes are modified for example, by random mutation, and screened to identify mutants that achieve this change in properties. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD that binds irreversibly to chitin.
1 . A reversible binding protein, comprising: a chitin-binding domain (CBD) containing a mutation such that the CBD binds to chitin under substantially the same conditions as the non-mutated CBD but the mutated CBD is capable of being eluted from chitin in a non-denaturing condition selected from: (a) modifying the pH of the eluting buffer; and (b) adding a reducing agent.
2 . A binding protein according to claim 1 , wherein the CBD is a mutated Bacillus CBD (BChBD).
3 . A binding protein according to claim 2 , wherein the mutation is P680H and V692I.
4 . A binding protein according to claim 1 , wherein the CBD is a Kluyveromyces CBD.
5 . A binding protein according to claim 4 , wherein the Kluyveromyces CBD (KIChBD) has a mutation at G524S or G524T and a C-terminal truncation.
6 . A binding protein according to claim 5 , wherein the CBD has at least one additional mutation at the C-terminal end of the truncated protein.
7 . A binding protein according to claim 6 , wherein at least one additional mutation is F542L, T543L or I544Y.
8 . A binding protein according to claim 1 , wherein the reducing agent is selected from β-mercaptoethanol and DTT.
9 . A binding protein according to claim 1 , wherein the pH is in the range of pH 5-10.
10 . A binding protein according to claim 9 , wherein the pH is in the range of 7-9.
11 . A method of screening for a mutant CBD capable of reversibly binding to CBD in non-denaturing conditions; comprising:
(a) forming a library of clones expressing fusion proteins wherein the fusion proteins each comprise a mutant CBD and a target protein;
(b) determining whether any of the fusion proteins are capable of binding to chitin and becoming dissociated under predetermined conditions; and
(c) assaying for residual fusion protein associated with chitin.